XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Jul. 12, 2021
Cover [Abstract]  
Document Type 8-K/A
Document Period End Date Jul. 12, 2021
Entity Registrant Name TEMPEST THERAPEUTICS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-35890
Entity Tax Identification Number 45-1472564
Entity Address, Address Line One 7000 Shoreline Court
Entity Address, Address Line Two Suite 275
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 415
Local Phone Number 798-8589
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TPST
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Description This Amendment No. 1 to Current Report on Form 8-K/A (the “8-K Amendment”) is being filed to amend the Current Report on Form 8-K of Tempest Therapeutics, Inc. (the “Company”) filed on July 12, 2021 (the “Original 8-K”). The Original 8-K included disclosure in Item 5.02 with respect to the appointment of Nicholas Maestas as vice president, strategy and finance and is the Company’s principal financial officer. This 8-K Amendment supplements and amends Item 5.02 to include a correction to a clerical error in the original filing, of which the Company became aware after the filing of the Original 8-K, with respect to the terms of the option grant made to Mr. Maestas.
Amendment Flag true
Entity Central Index Key 0001544227